Autolus Therapeutics

Yahoo Finance • 9 months ago

Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)

Autolus Therapeutics plc PDUFA Goal date is November 16, 2024 Company on track to submit a marketing authorization application to the European Medicines Agency (EMA) in the first half of 2024 LONDON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Aut... Full story

Yahoo Finance • 11 months ago

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)

BLA submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) Company on track to submit a marketing authorization application to the Europe... Full story

Yahoo Finance • 12 months ago

Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023

In-person and webcast event on Sunday, 10 December, 2023 at 8:00 AM PT / 4:00 PM GMT Review of pooled analysis of the ongoing FELIX Phase Ib/II study, pooled analysis from ALLCAR19 and FELIX Phase Ib studies and ALLCAR19 extension with obe... Full story

Yahoo Finance • last year

Autolus Therapeutics announces participation in upcoming conferences

LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its participation in three upcoming con... Full story

Yahoo Finance • last year

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations

obe-cel: oral presentation – pooled analysis of the ongoing FELIX Phase Ib/II study AUTO8: oral presentation of MCARTY Phase I Study obe-cel: poster presentation - pooled analysis from ALLCAR19 and FELIX Phase Ib studies and ALLCAR19 exten... Full story

Yahoo Finance • last year

Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US Food & Drug Administration (FDA) by en... Full story

Yahoo Finance • last year

Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus

LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will hold a virtual event on Tu... Full story

Yahoo Finance • last year

Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter... Full story

Yahoo Finance • last year

Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter... Full story

Yahoo Finance • last year

Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood

Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALLComplete responses observed in patients with CD19 negative disease No antigen negative relapse seen in responding patients LONDON, Sept. 05, 2023... Full story

Yahoo Finance • last year

Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia

Long-term CAR T cell persistence is associated with durable responses in B-ALLObe-cel CAR T cells can persist in patients at levels sufficient to allow their isolation from blood samples, even years after infusionSingle-cell analysis of pe... Full story

Yahoo Finance • last year

Autolus Therapeutics announces publication in Cancer Immunology Research

LONDON, June 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Cancer Immunology Rese... Full story

Yahoo Finance • last year

Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director

LONDON, June 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that Dr. Robert Iannone, Executive Vice... Full story

Yahoo Finance • last year

Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

At the highest dose 4 out of 4 PTCL patients achieved a response using the original manufacturing process (Process A)Ongoing complete metabolic responses in 2 out of 4 patients at 15 and 18-months post-dosing at the highest dose testedPres... Full story

Yahoo Finance • last year

Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA

LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for the pivotal Phase... Full story

Yahoo Finance • 2 years ago

Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL), on track for next data update at ASCO and EHA, with a Biologics License Application (BLA) submission to the US FDA p... Full story

Yahoo Finance • 2 years ago

Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO

LONDON, April 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for the pivotal Phas... Full story

Yahoo Finance • 2 years ago

Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner

Cardinal Health to provide core distribution capabilities required for U.S. commercialization of CAR T-cell therapiesInnovative Depot Model intended to reduce delivery time by allowing for transit while product release is finalized LONDON... Full story

Yahoo Finance • 2 years ago

Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting

- Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALL - Complete responses observed in patients with CD19 negative disease - No antigen negative relapse seen in responding patients LONDON, April 2... Full story

Yahoo Finance • 2 years ago

Autolus Therapeutics to Host Virtual Capital Markets Day

LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, will host a virtual Capital Markets Day on Thursday, A... Full story